Aileron Therapeutics, Inc. (ALRN) Financials

ALRN Assets vs Liabilities

DateAssetsLiabilities
Sept. 30, 2023 12.8 million 1.6 million
June 30, 2023 14.0 million 1.2 million
March 31, 2023 17.2 million 2.9 million
Dec. 31, 2022 22.0 million 3.4 million

ALRN Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Sept. 30, 2023 -1.6 million 229000
June 30, 2023 -3.1 million 300000
March 31, 2023 -4.7 million 391000
Dec. 31, 2022 -4.4 million 424000

ALRN Net Income

No data available :(

ALRN Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Sept. 30, 2023 12.1 million - -
June 30, 2023 13.7 million - -
March 31, 2023 16.7 million - -
Dec. 31, 2022 21.2 million - 33000

ALRN Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Sept. 30, 2023 4.5 million
June 30, 2023 4.5 million
March 31, 2023 4.5 million
Dec. 31, 2022 4.5 million

ALRN Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Sept. 30, 2023 - 22000 2.0 million -
June 30, 2023 - 187000 1.9 million -
March 31, 2023 - 1.8 million 2.2 million -
Dec. 31, 2022 - 2.4 million 2.3 million -

ALRN Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Sept. 30, 2023 - 12000
June 30, 2023 - 12000
March 31, 2023 - 43000
Dec. 31, 2022 - 43000

ALRN

Price: $2.11

52 week price:
1.61
7.42

Earnings Per Share: -2.88 USD

P/E Ratio: -1.64

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 28786

Ebitda: -6.4 million

Market Capitalization: 41.8 million

Links: